Entrada Therapeutics (TRDA) Treasury Shares (2020 - 2026)

Entrada Therapeutics has reported Treasury Shares for 6 years, with the latest figure at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Treasury Shares rose 3.35% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 3.35% YoY), and the FY2025 full-year result was $2.3 million, up 16.05% from the prior year.
• Treasury Shares for Q1 2026 stood at $2.8 million, up from $2.3 million in the prior quarter.
• The five-year high for Treasury Shares was $2.8 million in Q1 2026, with the low at $295104.0 in Q2 2022.
• Average Treasury Shares over 5 years is $1.3 million, with a median of $1.2 million recorded in 2023.
• Peak annual rise in Treasury Shares reached 437.67% in 2025, while the deepest fall reached 78.21% in 2025.
• Tracing TRDA's Treasury Shares over 5 years: stood at $463964.0 in 2022, then soared by 173.4% to $1.3 million in 2023, then jumped by 55.18% to $2.0 million in 2024, then climbed by 16.05% to $2.3 million in 2025, then climbed by 22.01% to $2.8 million in 2026.
• The last three Treasury Shares figures came in at $2.8 million (Q1 2026), $2.3 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.

Peer Comparison